The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease

被引:11
作者
Friedlander, Elizabeth A. [1 ]
Pallentino, Julia [2 ]
Miller, Sally K. [3 ]
VanBeuge, Susan S. [3 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
[2] GI Associates Tallahassee, Tallahassee, FL USA
[3] UNLV Sch Nursing, Dept Physiol Nursing, Las Vegas, NV USA
来源
JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS | 2010年 / 22卷 / 12期
关键词
PPI; GERD; esophagitis; acid suppression therapy; DELAYED-RELEASE FORMULATION; DEXLANSOPRAZOLE MR; EROSIVE ESOPHAGITIS; CLINICAL-TRIAL; PHARMACOKINETICS; OMEPRAZOLE; ARTICLE; GERD; LANSOPRAZOLE; PANTOPRAZOLE;
D O I
10.1111/j.1745-7599.2010.00578.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose: This article reviews the diagnosis and current treatment options for gastroesophageal reflux disease (GERD) available to nurse practitioners, with a focus on advances in proton pump inhibitor (PPI) therapy. Data Sources: Review of scientific literature and clinical management guidelines for GERD treatment and PPI therapy from the PubMed database, Google Scholar, and other World Wide Web resources. Conclusions: A number of safe and effective treatment options exist for GERD. Recent developments in PPI technology may begin to address unmet needs in PPI therapy. Implications for Practice: GERD is commonly diagnosed and treated by nurse practitioners in the primary care setting. Acid suppression therapy is the primary medical therapy for GERD. PPI therapy provides symptomatic relief of heartburn and regurgitation, as well as effective healing and maintenance of erosive esophagitis. Newer PPIs lengthen the duration of acid suppression and allow for more flexibility in dosing, which may improve medication adherence and decrease episodes of acid breakthrough.
引用
收藏
页码:674 / 683
页数:10
相关论文
共 67 条
  • [1] Long-term Safety Concerns with Proton Pump Inhibitors
    Ali, Tauseef
    Roberts, David Neil
    Tierney, William M.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2009, 122 (10) : 896 - 903
  • [2] [Anonymous], INF HEALTHC PROF UPD
  • [3] *ASTRAZENECA PHARM, 2008, NEXIUM ES MAGN PRESC
  • [4] *ASTRAZENECA PHARM, 2008, PRILOSEC OM PRESCR I
  • [5] DECREASED ORAL BIOAVAILABILITY OF LANSOPRAZOLE IN HEALTHY-VOLUNTEERS WHEN GIVEN WITH A STANDARDIZED BREAKFAST
    BERGSTRAND, R
    GRIND, M
    NYBERG, G
    OLOFSSON, B
    [J]. CLINICAL DRUG INVESTIGATION, 1995, 9 (02) : 67 - 71
  • [6] What Makes Individuals With Gastroesophageal Reflux Disease Dissatisfied With Their Treatment?
    Bytzer, Peter
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (08) : 816 - 822
  • [7] Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials
    Caro, JJ
    Salas, M
    Ward, A
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (07) : 998 - 1017
  • [8] Systematic review of endoscopic treatments for gastro-oesophageal reflux disease
    Chen, D.
    Barber, C.
    McLoughlin, P.
    Thavaneswaran, P.
    Jamieson, G. G.
    Maddern, G. J.
    [J]. BRITISH JOURNAL OF SURGERY, 2009, 96 (02) : 128 - 136
  • [9] Treatment patterns and symptom control in patients with GERD: US community-based survey
    Chey, William D.
    Mody, Reema R.
    Wu, Eric Q.
    Chen, Lei
    Kothari, Smita
    Persson, Bjorn
    Beaulieu, Nicolas
    Lu, Mei
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (08) : 1869 - 1878
  • [10] Chiba N, 1997, GASTROENTEROLOGY, V112, pA10